Cancer Medicine · global
Personalized mRNA Cancer Vaccine Succeeds in Phase 3, Reducing Melanoma Recurrence or Death Risk by 42%
A vaccine tailored to mutations in each patient’s tumor, combined with immunotherapy, helped more patients with high-risk melanoma remain recurrence-free two years after surgery. A large trial supports this strategy, but whether it extends life requires further follow-up.
For patients with high-risk melanoma, reducing the chance of cancer returning after surgical tumor removal is the next treatment challenge. Intismeran autogene, a personalized mRNA therapy jointly developed by Moderna and Merck, showed in a phase 3 trial that adding it to existing immunotherapy could further reduce the risk of recurrence or death, opening up a new possibility for adjuvant treatment after surgery.
The therapy is also known as V940 or mRNA-4157. On August 19, 2026, the two companies announced that the INTerpath-001 trial had met its primary endpoint of recurrence-free survival and its key secondary endpoint of distant metastasis-free survival; NDTV subsequently reported on its mechanism and clinical implications. Detailed data released on October 22 provided a measurable estimate of benefit beyond the initial announcement that the trial had succeeded.
INTerpath-001 enrolled 1,137 patients with stage IIB to IV cutaneous melanoma whose tumors had been completely resected. Using a randomized, double-blind design, the trial assigned patients in a two-to-one ratio to receive the vaccine plus KEYTRUDA (pembrolizumab), or placebo plus KEYTRUDA. The vaccine was administered every three weeks for up to nine doses; the trial evaluated whether adding the vaccine to immunotherapy could provide additional protection.
According to the analysis released by the companies, at a median follow-up of 24.6 months, the combination treatment group had a 42% lower risk of recurrence or death than the control group, with a hazard ratio of 0.58. Two-year recurrence-free survival rates were 82.2% and 70.0%, respectively, a difference of 12.2 percentage points. The risk of distant metastasis or death was also reduced by 38%. These results support a benefit in disease control, but do not yet establish that patients live longer overall.
The vaccine starts with the unique mutations in each patient’s tumor. Researchers analyze tumor samples and select neoantigens that may enable the immune system to recognize cancer cells. They then produce corresponding mRNA to prompt cells in the body to make the antigens and direct a T-cell response. Pembrolizumab, given alongside the vaccine, blocks the PD-1 immune checkpoint to reduce suppression of immune cells; the two treatments work by identifying targets and relieving immune suppression, respectively.
The companies said that no new safety signals emerged in the trial, but this does not mean the treatment has no side effects. Overall survival data remain immature, and follow-up will continue. The detailed results released so far come primarily from announcements by the companies developing the therapy, and more complete data are still needed to assess its long-term benefits and risks.
The study focused on patients who had undergone surgery but remained at risk of recurrence, and the vaccine is intended for therapeutic use. The two companies are discussing subsequent submissions with regulators; trial success itself does not mean marketing authorization has been granted. If the therapy enters routine medical care in the future, the time required for individualized design and manufacturing, quality control, and cost will together affect whether it can actually reach patients.